Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record

Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation

(2013) Mark H. Eckman   ANNALS OF INTERNAL MEDICINE

Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

(2012) Benjamin French et al.   Trials

The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

(2011) M A Perera et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record

(2011) J T Delaney et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A randomized controlled trial of genotype-based Coumadin initiation

(2011) James K Burmester et al.   GENETICS IN MEDICINE

Genetic Warfarin Dosing

(2011) Brian S. Finkelman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Accuracy of the Pharmacogenetic Dosing Table in the Warfarin Label in Predicting Initial Therapeutic Warfarin Doses in a Large, Racially Diverse Cohort

(2011) Jaekyu Shin et al.   PHARMACOTHERAPY

Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical Record

(2010) Marylyn D. Ritchie et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

(2010) N. A. Limdi et al.   BLOOD

A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans

(2010) D Voora et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans

(2010) L H Cavallari et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Principles of Human Subjects Protections Applied in an Opt-Out, De-identified Biobank

(2010) Jill Pulley et al.   CTS-Clinical and Translational Science

Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records

(2010) Logan Dumitrescu et al.   GENETICS IN MEDICINE

Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing

(2010) Nitin Roper et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Warfarin Genotyping Reduces Hospitalization Rates

(2010) Robert S. Epstein et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

MedEx: a medication information extraction system for clinical narratives

(2010) H. Xu et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort

(2010) Jaekyu Shin et al.   PHARMACOGENOMICS

VKORC1,CYP2C9andCYP4F2genetic-based algorithm for warfarin dosing: an Italian retrospective study

(2010) Carlo-Federico Zambon et al.   PHARMACOGENOMICS

Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study

(2010) Gwendolyn A McMillin et al.   THERAPEUTIC DRUG MONITORING

A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism

(2010) P.S. Wells et al.   THROMBOSIS RESEARCH

Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients

(2009) E Pautas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

(2009) Monica R McClain et al.   GENETICS IN MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing

(2009) Stuart A Scott et al.   PHARMACOGENOMICS

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

(2009) Rianne MF van Schie et al.   PHARMACOGENOMICS

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal

(2009) Daniel Kurnik et al.   PHARMACOGENOMICS

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Prospective Study of Warfarin Dosage Requirements Based on CYP2C9 and VKORC1 Genotypes

(2008) M-S Wen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized Medicine

(2008) DM Roden et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

VKORC1polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS

Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans

(2008) Nita A Limdi et al.   PHARMACOGENOMICS